Oral · GLP-1 agonist
KAI-7535 / HRS-7535
22 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
22
Active
7
Recruiting
3
Completed
13
Sites
36
Countries
2
Endpoints
185
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
9
Phase 1/2
1
Phase 2
7
Phase 3
5
Trials by status
Not yet recruiting
2
Recruiting
3
Active, not recruiting
2
Completed
13
Unknown
2
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
95
Weight & body composition
35
Glycemic / diabetes
31
Cardiometabolic biomarkers
9
Other (unclassified)
8
Renal / kidney
6
Cardiovascular outcomes
1
Most-measured metrics
Top 20 metrics across this asset's endpoints
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
22 of 22